The company operates as a specialized pharmaceutical entity providing radiopharmaceuticals for medical imaging, allergy immunotherapy extracts, and contract manufacturing for sterile injectable drugs. It also offers drug discovery services and generic formulations to global healthcare providers and pharmaceutical innovators.
The moat is supported by high switching costs in the CDMO sterile injectables business and regulatory licenses in the radiopharmaceutical segment. However, average ROCE of 10.7% suggests that these advantages do not yet translate into significant excess returns above the cost of capital.
Management is currently in a heavy reinvestment phase, spending significantly on new sterile fill-finish lines and PET pharmacy expansions. While they aim for net-zero debt by 2030, current returns are diluted by high capital expenditure and remediation costs at the Montreal facility.
The investment collapsed because the Montreal facility's regulatory issues escalated from a Warning Letter to a permanent import ban, crippling the core radiopharmaceutical segment. Management's heavy capital expenditure into sterile fill-finish lines failed to generate returns above the cost of capital, as the anticipated high-margin volume was offset by persistent remediation costs and supply shortages in SPECT products. By 2029, the goal of net-zero debt was abandoned to fund ongoing operational deficits, and the lack of pricing power in a competitive CDMO landscape left the company with stagnant earnings and a bloated balance sheet.
RichFakir rates Jubilant Pharmova Ltd's business quality as poor — 37/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Jubilant Pharmova Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Jubilant Pharmova Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Jubilant Pharmova Ltd's fair value is about ₹460 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →